Literature DB >> 16301317

The role of properdin in the assembly of the alternative pathway C3 convertases of complement.

Dennis E Hourcade1.   

Abstract

Complement is a powerful host defense system that contributes to both innate and acquired immunity. There are three pathways of complement activation, the classical pathway, lectin pathway, and alternative pathway. Each generates a C3 convertase, a serine protease that cleaves the central complement protein, C3. Nearly all the biological consequences of complement are dependent on the resulting cleavage products. Properdin is a positive regulator of complement activation that stabilizes the alternative pathway convertases (C3bBb). Properdin is composed of multiple identical protein subunits, with each subunit carrying a separate ligand-binding site. Previous reports suggest that properdin function depends on multiple interactions between its subunits with its ligands. In this study I used surface plasmon resonance assays to examine properdin interactions with C3b and factor B. I demonstrated that properdin promotes the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a surface. I also found that properdin binds to preformed alternative pathway C3 convertases. These findings support a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, can use its unoccupied C3b-binding sites as receptors for nascent C3b, bystander C3b, or pre-formed C3bB and C3bBb complexes. New C3bP and C3bBP intermediates can lead to in situ assembly of C3bBbP. The full stabilizing effect of properdin on C3bBb would be attained as properdin binds more than one ligand at a time, forming a lattice of properdin: ligand interactions bound to a surface scaffold.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301317     DOI: 10.1074/jbc.M508928200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  93 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Sarika Agarwal; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

3.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

4.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

5.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

6.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

Review 7.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

8.  Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.

Authors:  Martín Alcorlo; Agustín Tortajada; Santiago Rodríguez de Córdoba; Oscar Llorca
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

Review 9.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

10.  Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.

Authors:  Takashi Miwa; Sayaka Sato; Damodar Gullipalli; Masaomi Nangaku; Wen-Chao Song
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.